Drug intelligence / Profile preview

RN-564

Development stage: Phase 1
Lead developer: Pfizer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

RN-564 is a monoclonal antibody developed by Pfizer for the treatment of osteoporosis. It acts as an inhibitor of Dickkopf-related protein 1 (DKK1), a key regulator in bone metabolism that inhibits Wnt signaling and bone formation. By targeting DKK1, RN-564 aims to promote bone formation and counteract the effects of osteoporosis. The drug was investigated in phase 1 clinical trials for safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics in women with osteopenia and healthy men. As of the latest updates, no further development beyond phase 1 has been reported[1][2][5].

Other names: RN 564RN564RN-564

Targets

DKK1 (Dickkopf-related protein 1)

Beyond the preview

Go deeper on RN-564.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RN-564.

Explore the full profile